Jaw osteosarcoma models in mice: first description.
Animal experimentation
Bone resorption
Environment
Mandible
Models
Sarcoma
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
27 02 2019
27 02 2019
Historique:
received:
12
12
2018
accepted:
21
02
2019
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
21
4
2020
Statut:
epublish
Résumé
Osteosarcoma (OS) is the most common cancer of bone. Jaw osteosarcoma (JOS) is rare and it differs from other OS in terms of the time of occurrence (two decades later) and better survival. The aim of our work was to develop and characterize specific mouse models of JOS. Syngenic and xenogenic models of JOS were developed in mice using mouse (MOS-J) and human (HOS1544) osteosarcoma cell lines, respectively. An orthotopic patient-derived xenograft model (PDX) was also developed from a mandibular biopsy. These models were characterized at the histological and micro-CT imaging levels, as well as in terms of tumor growth and metastatic spread. Homogeneous tumor growth was observed in both the HOS1544 and the MOS-J JOS models by injection of 0.25 × 10 We describe the first animal model of JOS and its potential use for therapeutic applications. This model needs to be compared with the usual long-bone osteosarcoma models to investigate potential differences in the bone microenvironment.
Sections du résumé
BACKGROUND
Osteosarcoma (OS) is the most common cancer of bone. Jaw osteosarcoma (JOS) is rare and it differs from other OS in terms of the time of occurrence (two decades later) and better survival. The aim of our work was to develop and characterize specific mouse models of JOS.
METHODS
Syngenic and xenogenic models of JOS were developed in mice using mouse (MOS-J) and human (HOS1544) osteosarcoma cell lines, respectively. An orthotopic patient-derived xenograft model (PDX) was also developed from a mandibular biopsy. These models were characterized at the histological and micro-CT imaging levels, as well as in terms of tumor growth and metastatic spread.
RESULTS
Homogeneous tumor growth was observed in both the HOS1544 and the MOS-J JOS models by injection of 0.25 × 10
CONCLUSION
We describe the first animal model of JOS and its potential use for therapeutic applications. This model needs to be compared with the usual long-bone osteosarcoma models to investigate potential differences in the bone microenvironment.
Identifiants
pubmed: 30813941
doi: 10.1186/s12967-019-1807-5
pii: 10.1186/s12967-019-1807-5
pmc: PMC6391788
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
56Références
Crit Rev Oncol Hematol. 2012 Jun;82(3):280-95
pubmed: 21868246
Cell Mol Life Sci. 2015 Aug;72(16):3097-113
pubmed: 25935149
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Aug;106(2):254-7
pubmed: 18554951
Am J Cancer Res. 2017 Nov 01;7(11):2333-2349
pubmed: 29218254
Bonekey Rep. 2015 May 06;4:670
pubmed: 25987985
J Transl Med. 2015 Apr 30;13:136
pubmed: 25926029
Cancer Treat Rev. 2014 May;40(4):523-32
pubmed: 24345772
Cancer Res. 1994 Jun 1;54(11):3042-8
pubmed: 8187094
Cancer. 2014 Jul 1;120(13):2006-15
pubmed: 24705963
JAMA Otolaryngol Head Neck Surg. 2015 May 1;141(5):470-7
pubmed: 25811167
Stem Cells. 2014 May;32(5):1136-48
pubmed: 24446210
Cancer Res. 1992 Nov 15;52(22):6194-9
pubmed: 1423262
Pathobiology. 2016;83(4):170-6
pubmed: 27010922
Sarcoma. 2011;2011:694136
pubmed: 21403899
Oral Dis. 2007 Jan;13(1):82-7
pubmed: 17241435
Eur J Cancer Prev. 2010 May;19(3):173-81
pubmed: 20361423
J Transl Med. 2018 Apr 23;16(1):107
pubmed: 29688859
J Cell Biochem. 2018 Jun;119(6):4241-4250
pubmed: 29236321
J Oral Pathol Med. 2010 Oct;39(9):681-6
pubmed: 20701666
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
J Cancer Res Clin Oncol. 1996;122(9):559-65
pubmed: 8781571
J Oral Maxillofac Surg. 2011 Sep;69(9):2368-75
pubmed: 21288615
Bone. 2010 Nov;47(5):859-65
pubmed: 20696288
Front Oncol. 2014 Jul 18;4:189
pubmed: 25101245
In Vivo. 2002 Jul-Aug;16(4):223-8
pubmed: 12224130
Cancer. 2005 Dec 1;104(11):2522-9
pubmed: 16270320
J Bone Joint Surg Am. 2016 Jun 1;98(11):916-25
pubmed: 27252436
Crit Rev Oncol Hematol. 2006 Oct;60(1):1-8
pubmed: 16837208
Pediatr Blood Cancer. 2007 Dec;49(7):928-40
pubmed: 17066459
Ann Oncol. 2013 Mar;24(3):824-31
pubmed: 23131392
Sarcoma. 2013;2013:316123
pubmed: 23956680
Cancer Treat Res. 2009;152:3-13
pubmed: 20213383
J Hematol Oncol. 2017 May 12;10(1):106
pubmed: 28499452
Bone. 2013 Jul;55(1):166-78
pubmed: 23486187
J Cancer Res Clin Oncol. 2007 Mar;133(3):193-8
pubmed: 17031670